Focused on developing and commercializing prescription drug products, this biopharma company specializes in treatments for rare and orphan diseases. Investors monitor its pipeline progress and regulatory milestones, particularly for its lead candidate targeting a specific cardiovascular condition.
1 member of Congress has disclosed 1 trade in Acasti Pharma Inc. (ACST), a Healthcare company. The buy/sell breakdown shows 1 purchase versus 0 sales, indicating net buying interest from lawmakers. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
| Date | Politician | Type | Amount |
|---|---|---|---|
| 2021-03-16 | Mark Green | buy | $1K – $15K |